research use only
Cat.No.S4862
| Molecular Weight | 410.72 | Formula | C30H50 |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 111-02-4 | -- | Storage of Stock Solutions |
|
|
|
In vitro |
Ethanol : 100 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| In vitro |
Squalene is a triterpene that is an intermediate in the cholesterol biosynthesis pathway. In vitro experimental evidence indicates that this compound is a highly effective oxygen-scavenging agent and possesses antioxidant properties.
|
|---|---|
| In vivo |
Squalene appears to be critical in reducing free radical oxidative damage to the skin. It can effectively inhibit chemically induced skin tumorigenesis in rodents.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04555044 | Completed | Essential Fatty Acid Deficiency (EFAD) |
Baxter Healthcare Corporation |
January 22 2021 | Phase 4 |
| NCT03563222 | Terminated | Malnutrition Child |
Fresenius Kabi |
December 18 2019 | Phase 4 |
| NCT02476994 | Terminated | Essential Fatty Acid Deficiency (EFAD) |
Baxter Healthcare Corporation |
May 2015 | Phase 4 |
| NCT01902394 | Completed | Digestive Health and Immune Function |
Tufts University|General Mills|Tufts Medical Center |
June 2012 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.